The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms

Oncology Research

Volumn 18, Issue 7, 2010, Pages 343-347

  Heubner, Martin ^a   Wimberger, Pauline ^a   Riemann, Kathrin ^a   Kasimir Bauer, Sabine ^a   Otterbach, Friedrich ^b   Kimmig, Rainer ^a   Siffert, Winfried ^a  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

CYP1A1; Ovarian cancer; Platinum resistance; Polymorphism

Indexed keywords

CYTOCHROME P450 1A1; ISOLEUCINE; PLATINUM; VALINE;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; DISEASE COURSE; EPITHELIUM CELL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 77950558564     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504010X12626118079903     Document Type: Article

References (24)

1. Wernli, K. J.; Newcomb, P. A.; Hampton, J. M.; Trentham-Dietz, A.; Egan, K. M. Hormone therapy and ovarian cancer: Incidence and survival. Cancer Causes Control 19(6):605-613; 2008.
2. Syed, V.; Ulinski, G.; Mok, S. C.; Yiu, G. K.; Ho, S. M. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res. 61:6768-6776; 2001.
3. Cunat, S.; Hoffmann, P.; Pujol, P. Estrogens and epithelial ovarian cancer. Gynecol. Oncol. 94:25-32; 2004.
4. Makar, A. P. Hormone therapy in epithelial ovarian cancer. Endocr. Relat Cancer 7:85-93; 2000.
5. Papadimitriou, C. A.; Markaki, S.; Siapkaras, J.; Vlachos, G.; Efstathiou, E.; Grimani, I.; Hamilos, G.; Zorzou, M.; Dimopoulos, M. A. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 66:112-117; 2004.
6. Bowman, A.; Gabra, H.; Langdon, S. P.; Lessells, A.; Stewart, M.; Young, A.; Smyth, J. F. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: Identification of an endocrine-sensitive subgroup. Clin. Cancer Res. 8:2233-2239; 2002.
7. Cheung, L. W.; Au, S. C.; Cheung, A. N.; Ngan, H. Y.; Tombran-Tink, J.; Auersperg, N.; Wong, A. S. Pigment epithelium-derived factor is estrogen sensitive and inhibits the growth of human ovarian cancer and ovarian surface epithelial cells. Endocrinology 147:4179-4191; 2006.
8. Spink, D. C.; Eugster, H. P.; Lincoln, D. W.; Schuetz, J. D.; Schuetz, E. G.; Johnson, J. A.; Kaminsky, L. S.; Gierthy, J. F. 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1A1: A comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. Arch. Biochem. Biophys. 293:342-348; 1992.
9. McManus, M. E.; Burgess, W. M.; Veronese, M. E.; Huggett, A.; Quattrochi, L. C.; Tukey, R. H. Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P-450. Cancer Res. 50:3367-3376; 1990.
10. Aktas, D.; Guney, I.; Alikasifoglu, M.; Yuce, K.; Tuncbilek, E.; Ayhan, A. CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm. Gynecol. Oncol. 86:124-128; 2002.
11. Hayashi, S. I.; Watanabe, J.; Nakachi, K.; Kawajiri, K. PCR detection of an A/G polymorphism within exon 7 of the CYP1A1 gene. Nucleic Acids Res. 19:4797; 1991.
12. Crofts, F.; Taioli, E.; Trachman, J.; Cosma, G. N.; Currie, D.; Toniolo, P.; Garte, S. J. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 15:2961-2963; 1994.
13. Lee, K. R.; et al. Surface epithelial-stromal tumours. In: World Health Organization classification of tumours. Tumours of the breast and female genital organs. Lyon: IARC Press; 2003:117-145.
14. Silverberg, S. G. Histopathologic grading of ovarian carcinoma: A review and proposal. Int. J. Gynecol. Pathol. 19:7-15; 2000.
15. Agudo, A.; Sala, N.; Pera, G.; Capella, G.; Berenguer, A.; Garcia, N.; Palli, D.; Boeing, H.; Del, G. G.; Saieva, C.; Carneiro, F.; Berrino, F.; Sacerdote, C.; Tumino, R.; Panico, S.; Berglund, G.; Siman, H.; Stenling, R.; Hallmans, G.; Martinez, C.; Bilbao, R.; Barricarte, A.; Navarro, C.; Quiros, J. R.; Allen, N.; Key, T.; Bingham, S.; Khaw, K. T.; Linseisen, J.; Nagel, G.; Overvad, K.; Tjonneland, A.; Olsen, A.; Bueno-de-Mesquita, H. B.; Boshuizen, H. C.; Peeters, P. H.; Numans, M. E.; Clavel-Chapelon, F.; Boutron-Ruault, M. C.; Trichopoulou, A.; Lund, E.; Offerhaus, J.; Jenab, M.; Ferrari, P.; Norat, T.; Riboli, E.; Gonzalez, C. A. Polymorphisms in metabolic genes related to tobacco smoke and the risk of gastric cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol. Biomarkers Prev. 15:2427-2434; 2006.
16. Sillanpaa, P.; Heikinheimo, L.; Kataja, V.; Eskelinen, M.; Kosma, V. M.; Uusitupa, M.; Vainio, H.; Metsola, K.; Hirvonen, A. CYP1A1 and CYP1B1 genetic polymorphisms, smoking and breast cancer risk in a Finnish Caucasian population. Breast Cancer Res. Treat. 104:287-297; 2007.
17. Perez, R. P. Cellular and molecular determinants of cisplatin resistance. Eur. J. Cancer 34:1535-1542; 1998.
18. Saldivar, J. S.; Wu, X.; Follen, M.; Gershenson, D. Nucleotide excision repair pathway review I: Implications in ovarian cancer and platinum sensitivity. Gynecol. Oncol. 107:S56-S71; 2007.
19. Steffensen, K. D.; Waldstrom, M.; Jeppesen, U.; Brandslund, I.; Jakobsen, A. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Int. J. Gynecol. Cancer 18:702-710; 2008.
20. LeBlanc, G. A.; Sundseth, S. S.; Weber, G. F.; Waxman, D. J. Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res. 52:540-547; 1992.
21. Masubuchi, Y.; Kawasaki, M.; Horie, T. Down-regulation of hepatic cytochrome P450 enzymes associated with cisplatin-induced acute renal failure in male rats. Arch. Toxicol. 80:347-353; 2006.
22. Hildebrandt, A. G.; Schwarz, D.; Krusekopf, S.; Kleeberg, U.; Roots, I. Recalling P446. P4501A1 (CYP1A1) opting for clinical application. Drug Metab Rev. 39:323-341; 2007.
23. Schoket, B.; Papp, G.; Levay, K.; Mrackova, G.; Kadlubar, F. F.; Vincze, I. Impact of metabolic genotypes on levels of biomarkers of genotoxic exposure. Mutat. Res. 482:57-69; 2001.
24. Zwelling, L. A.; Kohn, K. W. Mechanism of action of cis- dichlorodiammineplatinum(II). Cancer Treat. Rep. 63:1439-1444; 1979.